Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for GMP Manufacture of RNA

STONY BROOK, NY / ACCESSWIRE / July 29, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN), a leader in PCR-based DNA technologies, will present a poster at the 4th Annual mRNA-based Therapeutics Summit in Boston. The poster introduces the Linea™ IVT platform, which utilizes an enzymatically produced DNA template and next-generation RNA polymerase to enhance mRNA manufacturing. This platform addresses double-stranded RNA (dsRNA) contamination, providing a simplified workflow for mRNA producers.

The poster, titled "Reduction of dsRNA Contamination in High-Yield mRNA Production," will be presented by Clay Shorrock and his team on July 30, 2024, from 3:45 - 4:30 p.m. local time. Shorrock emphasized the importance of dsRNA reduction for efficient mRNA expression, regulatory compliance, and reducing undesired immunogenicity.

Linea IVT offers a fully enzymatic solution to minimize dsRNA impurities without compromising yields. The platform is positioned to support the development of transformative mRNA-based therapeutics and vaccines.